Search

Summary Adiponectin, visfatin, and omentin are adipokines involved in insulin sensitivity. Neuropeptide Y (NPY) and its receptors, Y1R, Y2R, and Y5R, are involved in appetite regulation. Here we examined the correlations between these two hormones groups in subcutaneous and visceral adipose tissues. We demonstrated that in subcutaneous adipose tissue, the adiponectin , visfatin and omentin expression positively correlated with that of subcutaneous NPY . Subcutaneous adiponectin expression positively correlated with subcutaneous Y1R and Y5R . Subcutaneous visfatin expression positively correlated with subcutaneous Y1R , Y2R , and Y5R . Subcutaneous omentin expression positively correlated with subcutaneous Y5R . In visceral adipose tissue, adiponectin , visfatin and omentin expression positively correlated with visceral NPY . Visceral visfatin expression positively correlated with visceral Y1R , Y2R and Y5R . There was no correlation between the subcutaneous and visceral expression of these adipokines and receptors. BMI correlated better with visceral adipocyte characteristics including width, height, perimeter, and area than with those of subcutaneous adipocyte. Visceral, but not subcutaneous, adipocyte parameters positively correlated with insulin and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), but negatively associated with Quantitative Insulin Sensitivity Check Index (QUICKI). These results suggest that adiponectin , omentin , and visfatin expression correlated with NPY expression in either type of adipose tissue, with no evidence of cross-linking between adipose tissue depots, suggesting that there might be (a) different regulation mechanism(s) between subcutaneous and visceral adipose tissues with regard to expressions of these two hormone groups. Further studies are required to identify factors that regulate the linkage between these hormones in each adipose tissue type. [ABSTRACT FROM AUTHOR]

Adiponectin, visfatin, and omentin are adipokines involved in insulin sensitivity. This study aimed to determine interactions between these adipokines in subcutaneous and visceral fat and in serum, and their associations with clinical factors. Adiponectin was present at the highest levels in subcutaneous and visceral fat and serum. Subcutaneous adiponectin showed positive correlations with serum adiponectin and the quantitative insulin sensitivity check index (QUICKI). Serum adiponectin correlated positively with QUICKI and serum omentin-1 but negatively with body weight, BMI, and homeostasis model assessment of insulin resistance (HOMA-IR). Subcutaneous omentin correlated positively with QUICKI but negatively with waist and hip circumferences. Serum omentin-1 correlated positively with QUICKI but negatively with body weight, BMI, waist and hip circumferences, weight gain, and HOMA-IR. Serum visfatin correlated positively with serum omentin-1 and negatively with weight gain. Serum peptide YY (PYY) levels were correlated positively with subcutaneous visfatin but negatively with visceral visfatin. Positive correlations were observed between subcutaneous expression of adiponectin, visfatin, and omentin and visceral expression of these genes. Multiple linear regression analysis showed that serum adiponectin was associated with BMI and QUICKI. Serum omentin-1 could be predicted from BMI, QUICKI, and weight gain. Weight gain, serum adiponectin, omentin-1, and DBP could be used to predict serum visfatin. In conclusion, adiponectin and omentin from subcutaneous fat displayed correlations with decreased obesity and increased insulin sensitivity while visfatin showed an association with serum PYY and weight gain. The expressions of these adipokines were correlated within each type of fat but not between different fat depots. [ABSTRACT FROM AUTHOR]